Realm Therapeutics (AIM: RLM) is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology. Realm Therapeutics is advancing its immunomodulatory technology against inflammatory diseases with high unmet needs in Dermatology and Ophthalmology. The Company has developed proprietary formulations of our novel technology for initial application in Atopic Dermatitis (PR022), Acne (PR023) and Allergic Conjunctivitis (PR013), as reflected in our pipeline chart at @ www.realmtx.com